Gastrointestinal Cancers

15 protocols meet the specified criteria.
  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
  • EA2176

    A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
  • EA2192

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
  • EA2197

    Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)
  • EAY191-A3

    A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancer
  • EAY191-A6

    A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations
  • NRG-CC005

    Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)
  • NRG-GI008

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
  • S2012

    Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
  • S2013

    Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
  • S2107

    Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer

    Targeted Intra-arterial Gemcitabine vs Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer
  • WVU010220

    Phase I/II Study of Neoadjuvant FOLFIRINOX in Combination with Peri-Operative Oral Hydroxychloroquine (FHQ) in Subjects with Resectable Adenocarcinoma of the Pancreas
  • WVU020220

    Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma